Tokyo, June 4 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061763) titled 'ALECENSA Drug Use Surveillance' on June 2.
Study Type:
Observational
Primary Sponsor:
Institute - Chugai Pharmaceutical Co. Ltd
Condition:
Condition - To confirm the following under actual conditions of use of Alectinib Hydrochloride Capsules (hereinafter, this drug) in ALK fusion gene-positive patients with advanced or recurrent solid tumors
Non-small cell lung cancer (NSCLC) and inflammatory myofifibroblastic tumors (IMT): Safety in children (under 16 years old)
NSCLC and Non-IMT Solid Carcinomas: Efficacy and Safety
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objecti...